
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera is favored because its dominant >90% share in a $15B+ MRD market gives it a durable competitive moat, supported by strong reimbursement coverage, growing clinical adoption, and management’s track record of upward revisions. Signatera remains the key earnings engine, with ~60% volume growth in 2025, a current ASP of $1,275 versus a $3,590 Medicare rate, and a credible path toward 70%+ gross margin and 25%+ EBIT over time as COGS have already fallen more than $100 since 2022. The outlook is further strengthened by pipeline catalysts in ultra-sensitive Signatera Genome, pharma data monetization, and early cancer detection, where management sees roughly $1.5B of incremental revenue potential from colorectal screening alone.
Bears say
Natera is viewed negatively because its growth story depends heavily on MRD adoption, yet penetration in established uses like CRC adjuvant already exceeds 50%, limiting incremental upside while expansion into other cancers may stall. Competitive pressures are intensifying across MRD and Women’s Health, and the company’s catalysts have been inconsistent, with delayed guideline updates, failed trials, and reliance on factors outside management’s control. Although MRD ASPs have risen from roughly $500 to $1,250 over the past five years, further progress toward $2,000 may not be linear, leaving revenue and margin assumptions vulnerable if reimbursement or share gains slow.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Natera (NTRA) Forecast
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares